The Medical Letter on Drugs and Therapeutics
ONLINE
ONLY
ARTICLE
November 10, 2014
View Complete Issue         Table of Contents 2019 
Obinutuzumab (Gazyva) for Chronic Lymphocytic Leukemia (online only)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Obinutuzumab (Gazyva) for Chronic Lymphocytic Leukemia (online only)
November 10, 2014 (Issue: 1455)
Obinutuzumab (Gazyva – Genentech), a humanized anti-CD20 monoclonal antibody, has been approved by the FDA for use in combination with chlorambucil (Leukeran) in patients with previously untreated chronic lymphocytic leukemia (CLL). Two other...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Obinutuzumab (Gazyva) for Chronic Lymphocytic Leukemia (online only)
Article code: 1455d
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.